Oncology has been rapidly evolving over the past decade with tremendous therapeutic development. Engineered cell therapies such as chimeric antigen receptor (CAR)-T cells are increasingly used in daily practice, and provided a paradigm change especially for hematological malignancies. Their development is a scientific and technological achievement, but their toxicities can be life-threatening. As their utilization expands, better understanding of pathophysiology leads to better management. In this article we present a general overview of cell-therapy toxicities and their management.
Keywords: Cytokine release syndrome; Immuneffektorzell-assoziiertes Neurotoxizitätssyndrom; Syndrome de libération cytokinique; Zelltherapien; Zytokinfreisetzungssyndrom; cell therapies; chimeric antigen receptor; chimärer Antigenrezeptor; immune effector cell-associated neurotoxicity syndrome; récepteur d’antigène chimérique; syndrome de neurotoxicité associé aux cellules effectrices du système immunitaire; thérapies cellulaires.